SENTINEL SPECTRUM- milbemycin oxime, lufenuron and praziquantel tablet, chewable
Sentinel Spectrum by
Drug Labeling and Warnings
Sentinel Spectrum by is a Animal medication manufactured, distributed, or labeled by Merck Sharp & Dohme Corp., Virbac Corporation. Drug facts, warnings, and ingredients follow.
Drug Details [pdf]
- SPL UNCLASSIFIED SECTION
- WARNINGS
-
DESCRIPTION
Description: SENTINEL® SPECTRUM® Chews are available in four strengths in color-coded packages for oral administration to dogs and puppies according to their weight. Each chewable flavored tablet is formulated to provide a minimum of 0.23 mg/pound (0.5mg/kg) of milbemycin oxime, 4.55 mg/pound (10mg/kg) of lufenuron, and 2.28 mg/pound (5mg/kg) of praziquantel.
Milbemycin oxime consists of the oxime derivatives of 5-didehydromilbemycins in the ratio of approximately 80% A4 (C32H45NO7, MW 555.71) and 20% A3 (C31H43NO7, MW 541.68). Milbemycin oxime is classified as a macrocyclic anthelmintic.
Lufenuron is a benzoylphenylurea derivative with the following chemical composition: N-[2,5-dichloro-4-(1,1,2,3,3,3,-hexafluoropropoxy)-phenyl-aminocarbonyl]-2,6-difluorobenzamide (C17H8CI2F8N2O3, MW 511.15). Benzoylphenylurea compounds, including lufenuron, are classified as insect development inhibitors (IDIs).
Praziquantel is an isoquinolone anthelmintic with the chemical name 2-(Cyclohexylcarbonyl)-1,2,3,6,7,-11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one.
-
INDICATIONS & USAGE
Indications: SENTINEL SPECTRUM Chews are indicated for the prevention of heartworm disease caused by Dirofilaria immitis; for the prevention and control of flea populations (Ctenocephalides felis); and for the treatment and control of adult roundworm (Toxocara canis, Toxascaris leonina), adult hookworm (Ancylostoma caninum), adult whipworm (Trichuris vulpis), and adult tapeworm (Dipylidium caninum, Taenia pisiformis, Echinococcus multilocularis and Echinococcus granulosus) infections in dogs and puppies two pounds of body weight or greater and six weeks of age and older.
-
DOSAGE & ADMINISTRATION
Dosage and Administration: SENTINEL SPECTRUM Chews should be administerd orally, once every month, at the minimum dosage of 0.23 mg/lb (0.5 mg/kg) milbemycin oxime, 4.55 mg/lb (10 mg/kg) lufenuron, and 2.28 mg/lb (5 mg/kg) praziquantel. For heartworm prevention, give once monthly for at least 6 months after exposure to mosquitoes (see EFFECTIVENESS).
Dosage Schedule Body Weight Milbemycin Oxime per chewable Lufenuron per chewable Praziquantel per chewable Number of chewables 2 to 8 lbs. 2.3 mg 46 mg 22.8 mg One 8.1 to 25 lbs. 5.75 mg 115 mg 57 mg One 25.1 to 50 lbs. 11.5 mg 230 mg 114 mg One 50.1 to 100 lbs. 23.0 mg 460 mg 228 mg One Over 100 lbs. Administer the appropriate combination of chewables To ensure adequate absorption, always administer SENTINEL SPECTRUM Chews to dogs immediately after or in conjunction with a normal meal.
SENTINEL SPECTRUM Chews may be offered to the dog by hand or added to a small amount of dog food. The chewables should be administered in a manner that encourages the dog to chew, rather than to swallow without chewing. Chewables may be broken into pieces and fed to dogs that normally swallow treats whole. Care should be taken that the dog consumes the complete dose, and treated animals should be observed a few minutes after administration to ensure that no part of the dose is lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.
Heartworm Prevention: SENTINEL SPECTRUM Chews should be administered at monthly intervals beginning within one month of the dog's first seasonal exposure to mosquitoes and continuing until at least 6 months after the dog's last seasonal exposure (see EFFECTIVENESS). SENTINEL SPECTRUM Chews may be administered year-round without interruption. When switching from another heartworm preventative product to SENTINEL SPECTRUM Chews, the first dose of SENTINEL SPECTRUM Chews should be given within a month of the last dose of the former product.
Flea Treatment and Prevention: Treatment with SENTINEL SPECTRUM Chews may begin at any time of the year, preferably starting one month before fleas become active and continuing monthly through the end of flea season. In areas where fleas are common year-round, monthly treatment with SENTINEL SPECTRUM Chews should continue the entire year without interruption.
To minimize the likelihood of flea reinfestation, it is important to treat all animals within a household with an approved flea protection product, as necessary.
Intestinal Nematode and Cestode Treatment and Control: Dogs may be exposed to and can become infected with roundworms, whipworms, hookworms, and tapeworms throughout the year, regardless of season or climate. Clients should be advised of appropriate measures to prevent reinfection of their dog with intestinal parasites. Because the prepatent period for E. multilocularis may be as short as 26 days, dogs treated at the labeled monthly intervals may become reinfected and shed eggs between treatments.
- CONTRAINDICATIONS
- WARNINGS
-
PRECAUTIONS
Precautions: Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention (see EFFECTIVENESS).
Prior to administration of SENTINEL SPECTRUM Chews, dogs should be tested for existing heartworm infections. At the discretion of the veterinarian, infected dogs should be treated to remove adult heartworms. SENTINEL SPECTRUM Chews are not effective against adult D. immitis.
Mild, transient hypersensitivity reactions, such as labored breathing, vomiting, hypersalivation, and lethargy have been noted in some dogs treated with milbemycin oxime carrying a high number of circulating microfilariae. These reactions are presumably caused by release of protein from dead or dying microfilariae.
Do not use in puppies less than six weeks of age.
Do not use in dogs or puppies less than two pounds of body weight.
The safety of SENTINEL® SPECTRUM® Chews has not been evaluated in dogs used for breeding or in lactating females. Studies have been performed with milbemycin oxime and lufenuron alone (see ANIMAL SAFETY).
-
ADVERSE REACTIONS
Adverse Reactions: The following adverse reactions have been reported in dogs after administration of milbemycin oxime, lufenuron, or praziquantel: vomiting, depression/lethargy, pruritus, urticaria, diarrhea, anorexia, skin congestion, ataxia, convulsions, salivation, and weakness.
To report suspected adverse drug events, contact Merck Animal Health at 1-800-224-5381. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.
For technical assistance, call Merck Animal Health at 1-800-224-5318.
-
SPL UNCLASSIFIED SECTION
Information for Owner or Person Treating Animal: Echinococcus multilocularis and Echinococcus granulosus are tapeworms found in wild canids and domestic dogs. E. multilocularis and E. granulosus can infect humans and cause serious disease (alveolar hydatid disease and hydatid disease, respectively). Owners of dogs living in areas where E. multilocularis or E. granulosus are endemic should be instructed on how to minimize their risk of exposure to these parasites, as well as their dog's risk of exposure. Although SENTINEL SPECTRUM Chews were 100% effective in laboratory studies in dogs against E. multilocularis and E. granulosus, no studies have been conducted to show that the use of this product will decrease the incidence of alveolar hydatid disease or hydatid disease in humans. Because the prepatent period for E. multilocularis may be as short as 26 days, dogs treated at the labeled monthly intervals may become reinfected and shed eggs between treatments.
-
Effectiveness
Heartworm Prevention: In a well-controlled laboratory study, SENTINEL SPECTRUM Chews (milbemycin oxime, lufenuron, praziquantel) were 100% effective against induced heartworm infections when administered once monthly for 6 consecutive months. In well-controlled laboratory studies, neither one dose nor two consecutive doses of SENTINEL SPECTRUM Chews provided 100% effectiveness against induced heartworm infections.
Intestinal Nematodes and Cestodes Treatment and Control: Elimination of the adult stage of hookworm (Ancylostoma caninum), roundworm (Toxacara canis, Toxascaris leonina), whipworm (Trichuris vulpis) and tapeworm (Dipylidium caninum, Echinococcus multilocularis, Echinococcus granulosus, Taenia pisiformis) infections in dogs was demonstrated in well-controlled laboratory studies.
-
SPL UNCLASSIFIED SECTION
Animal Safety: In a margin of safety study, 40 ten-week-old puppies (10 per group) were administered either a sham dose (0X) or doses of 1, 3, or 5X the maximum exposure dose of SENTINEL SPECTRUM Chews once every two weeks for a total of seven treatments. Transient ataxia, lethargy, tremors, and salivation were seen in the 3X and 5X groups following each of the seven doses. Lethargy and ataxia were occasionally reported in sham-dosed (0X) and 1X dogs. Tremors were observed twice post-treatment in the 1X treatment group. Vomiting was seen in all treatment groups but at a higher incidence in the 3X and 5X groups. At the 5X dose, shallow breathing was noted in two dogs and one dog was unable to stand following two different doses. All clinical signs resolved within 24 hours.
In a second margin of safety study, 64 six-week-old puppies (16 per group) were dosed with either a sham (0X) or 1, 3, or 5X the maximum exposure dose of SENTINEL SPECTRUM Chews on days 1, 15, 29, and 43. A dose dependent increase in ataxia, decreased activity, tremors, and salivation was seen within 24 hours of treatment. Splayed hind limbs were observed once in one dog in the 5X treatment group. Vomiting was observed in the 5X treatment group.
For SENTINEL SPECTRUM Chews, the maximum exposure based on product dosing is 2.5 mg/kg for milbemycin oxime, 50.7 mg/kg for lufenuron and 25.1 mg/kg for praziquantel, which is higher than the minimum effective dose used in the safety studies for milbemycin oxime and lufenuron (see below).
Milbemycin Oxime: Two studies were conducted in heartworm-infected dogs treated with milbemycin oxime. Mild, transient hypersensitivity reactions were observed in dogs with high microfilariae counts (see PRECAUTIONS).
Safety studies in pregnant dogs demonstrated that doses of 0.6X the maximum exposure dose of SENTINEL SPECTRUM Chews, (1.5 mg/kg of milbemycin oxime), administered daily from mating through weaning, resulted in measurable concentrations of milbemycin oxime in milk. Puppies nursing these females demonstrated milbemycin oxime-related effects (depression, decreased activity, diarrhea, dehydration, nasal discharge). A subsequent study, which evaluated the daily administration of 0.6X the maximum exposure dose of SENTINEL SPECTRUM Chews, from mating until one week before weaning, demonstrated no effects on the pregnant females or their litters. A study, in which pregnant females were dosed once, at 0.6X maximum exposure dose of SENTINEL SPECTRUM Chews before, on the day of, or shortly after whelping, resulted in no effects on the puppies.
Some nursing puppies, at 2, 4, and 6 weeks of age, administered oral doses of 9.6 mg/kg milbemycin oxime (3.8X the maximum exposure dose of SENTINEL SPECTRUM Chews) exhibited tremors, vocalization, and ataxia. These effects were all transient and puppies returned to normal within 24 to 48 hours. No effects were observed in puppies administered 0.5 mg/kg milbemycin oxime (minimum label dose).
A rising-dose safety study conducted in rough-coated Collies resulted in ataxia, pyrexia, and periodic recumbency in one of fourteen dogs administered milbemycin oxime at 12.5 mg/kg (5X the maximum exposure dose of SENTINEL SPECTRUM Chews). Prior to receiving the 12.5 mg/kg dose on day 56 of the study, all animals had undergone a dosing regimen consisting of 2.5 mg/kg milbemycin oxime on day 0, followed by 5.0 mg/kg on day 14, and 10.0 mg/kg on day 32. No adverse reactions were observed in any of the Collies treated with doses less than 12.5 mg/kg.
Lufenuron: In a ten-month study, doses of lufenuron up to 2X the maximum exposure dose of SENTINEL SPECTRUM Chews (10 mg/kg) caused no overt toxicity. A single dose of 200 mg/kg had no marked effect on adult dogs, but caused decreased activity and reduced appetite in eight-week-old puppies. Lufenuron tablets were evaluated with concurrent administration of flea adulticides containing carbaryl, permethrin, chlorpyriphos, and cythioate. No toxicty resulted from these combinations. Lufenuron tablets did not cause cholinesterase inhibition nor did they enhance cholinesterase inhibition caused by exposure to organophoshphates.
Two laboratory and two well-controlled field studies were conducted to evaluate reproductive safety of lufenuron tablets in breeding dogs. In one of the laboratory studies, in which lufenuron was administered to Beagle dogs as three divided doses, equivalent to 17.8X the maximum exposure dose of SENTINEL SPECTRUM Chews (10 mg/kg), the ratio of gravid females to females mated was 8/8 or 100% in the control group and 6/9 or 67% in the lufenuron-treated group. The mean number of pups per litter was two animals higher in the lufenuron versus control groups and mean birth weights of pups from treated females in this study was lower than control groups. These pups grew at a similar rate to the control pups. The incidence of nasal discharge, pulmonary congestion, diarrhea/dehydration, and sluggishness was higher in the lufenuron-treated pup group than in the control pup group. The incidence of these signs was transient and decreasing by the end of lactation.
Results from three additional reproductive safety studies, one laboratory and two field studies, evaluating eleven breeds of dogs, did not demonstrate any adverse findings for the reproductive parameters measured, including fertility, pup birth weights, and pup clinical signs, after administration of lufenuron up to 1X the maximum exposure dose of SENTINEL SPECTRUM Chews. The average milk: blood concentration ratio was approximately 60 (i.e. 60X higher drug concentrations in the milk compared to drug levels in the blood of treated females). Nursing puppies averaged 8-9 times higher blood concentrations of lufenuron compared to their dams.
- STORAGE AND HANDLING
- HOW SUPPLIED
- SPL UNCLASSIFIED SECTION
-
PRINCIPAL DISPLAY PANEL - 6 Chewable Blister Pack Carton - 5354-02
MERCK
Animal Health2-8lbs
FOR DOGS AND PUPPIES
SIX WEEKS OF AGE AND OLDERBroad Spectrum
Parasiticide- prevents heartworm
disease - prevents and controls
flea populations - treats and controls
tapeworms, whipworms
roundworms, hookworms - give with a meal
once a month
sentinel®
spectrum® chews
(milbemycin oxime lufenuron praziquantel)6 chewables
2.3 mg milbemycin oxime 46 mg lufenuron 22.8 mg praziquantel
CAUTION: Federal (USA) law resricts this drug to use by or on the order of a licensed veterinarian
- prevents heartworm
-
PRINCIPAL DISPLAY PANEL - 6 Chewable Blister Pack Carton - 5355-02
MERCK
Animal Health8.1-25lbs
FOR DOGS AND PUPPIES
SIX WEEKS OF AGE AND OLDERBroad Spectrum
Parasiticide- prevents heartworm
disease - prevents and controls
flea populations - treats and controls
tapeworms, whipworms
roundworms, hookworms - give with a meal
once a month
sentinel®
spectrum® chews
(milbemycin oxime lufenuron praziquantel)6 chewables
5.75 mg milbemycin oxime 115 mg lufenuron 57 mg praziquantel
CAUTION: Federal (USA) law resricts this drug to use by or on the order of a licensed veterinarian
- prevents heartworm
-
PRINCIPAL DISPLAY PANEL - 6 Chewable Blister Pack Carton - 5356-02
MERCK
Animal Health25.1-50lbs
FOR DOGS AND PUPPIES
SIX WEEKS OF AGE AND OLDERBroad Spectrum
Parasiticide- prevents heartworm
disease - prevents and controls
flea populations - treats and controls
tapeworms, whipworms
roundworms, hookworms - give with a meal
once a month
sentinel®
spectrum® chews
(milbemycin oxime lufenuron praziquantel)6 chewables
11.5 mg milbemycin oxime 230 mg lufenuron 114 mg praziquantel
CAUTION: Federal (USA) law resricts this drug to use by or on the order of a licensed veterinarian
- prevents heartworm
-
PRINCIPAL DISPLAY PANEL - 6 Chewable Blister Pack Carton - 5357-02
MERCK
Animal Health50.1-100lbs
FOR DOGS AND PUPPIES
SIX WEEKS OF AGE AND OLDERBroad Spectrum
Parasiticide- prevents heartworm
disease - prevents and controls
flea populations - treats and controls
tapeworms, whipworms
roundworms, hookworms - give with a meal
once a month
sentinel®
spectrum® chews
(milbemycin oxime lufenuron praziquantel)6 chewables
23 mg milbemycin oxime 460 mg lufenuron 228 mg praziquantel
CAUTION: Federal (USA) law resricts this drug to use by or on the order of a licensed veterinarian
- prevents heartworm
-
INGREDIENTS AND APPEARANCE
SENTINEL SPECTRUM
milbemycin oxime, lufenuron and praziquantel tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 0061-5354 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength MILBEMYCIN OXIME (UNII: 0502PUN0GT) (MILBEMYCIN OXIME - UNII:0502PUN0GT) MILBEMYCIN OXIME 2.3 mg LUFENURON (UNII: 1R754M4918) (LUFENURON - UNII:1R754M4918) LUFENURON 46 mg PRAZIQUANTEL (UNII: 6490C9U457) (PRAZIQUANTEL - UNII:6490C9U457) PRAZIQUANTEL 22.8 mg Product Characteristics Color BROWN Score no score Shape OVAL Size 12mm Flavor Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 0061-5354-01 1 in 1 CARTON 1 6 in 1 BLISTER PACK 2 NDC: 0061-5354-02 2 in 1 CARTON 2 6 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141333 12/08/2011 SENTINEL SPECTRUM
milbemycin oxime, lufenuron and praziquantel tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 0061-5355 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength MILBEMYCIN OXIME (UNII: 0502PUN0GT) (MILBEMYCIN OXIME - UNII:0502PUN0GT) MILBEMYCIN OXIME 5.75 mg LUFENURON (UNII: 1R754M4918) (LUFENURON - UNII:1R754M4918) LUFENURON 115 mg PRAZIQUANTEL (UNII: 6490C9U457) (PRAZIQUANTEL - UNII:6490C9U457) PRAZIQUANTEL 57 mg Product Characteristics Color BROWN Score no score Shape OVAL Size 17mm Flavor Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 0061-5355-01 1 in 1 CARTON 1 6 in 1 BLISTER PACK 2 NDC: 0061-5355-02 2 in 1 CARTON 2 6 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141333 12/08/2011 SENTINEL SPECTRUM
milbemycin oxime, lufenuron and praziquantel tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 0061-5356 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength MILBEMYCIN OXIME (UNII: 0502PUN0GT) (MILBEMYCIN OXIME - UNII:0502PUN0GT) MILBEMYCIN OXIME 11.5 mg LUFENURON (UNII: 1R754M4918) (LUFENURON - UNII:1R754M4918) LUFENURON 230 mg PRAZIQUANTEL (UNII: 6490C9U457) (PRAZIQUANTEL - UNII:6490C9U457) PRAZIQUANTEL 114 mg Product Characteristics Color BROWN Score no score Shape OVAL Size 20mm Flavor Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 0061-5356-01 1 in 1 CARTON 1 6 in 1 BLISTER PACK 2 NDC: 0061-5356-02 2 in 1 CARTON 2 6 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141333 12/08/2011 SENTINEL SPECTRUM
milbemycin oxime, lufenuron and praziquantel tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 0061-5357 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength MILBEMYCIN OXIME (UNII: 0502PUN0GT) (MILBEMYCIN OXIME - UNII:0502PUN0GT) MILBEMYCIN OXIME 23 mg LUFENURON (UNII: 1R754M4918) (LUFENURON - UNII:1R754M4918) LUFENURON 460 mg PRAZIQUANTEL (UNII: 6490C9U457) (PRAZIQUANTEL - UNII:6490C9U457) PRAZIQUANTEL 228 mg Product Characteristics Color BROWN Score no score Shape OVAL Size 23mm Flavor Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 0061-5357-01 1 in 1 CARTON 1 6 in 1 BLISTER PACK 2 NDC: 0061-5357-02 2 in 1 CARTON 2 6 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141333 12/08/2011 Labeler - Merck Sharp & Dohme Corp. (001317601) Establishment Name Address ID/FEI Business Operations Virbac Corporation 829166276 MANUFACTURE
Trademark Results [Sentinel Spectrum]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 SENTINEL SPECTRUM 78266780 not registered Dead/Abandoned |
Novartis AG 2003-06-25 |
 SENTINEL SPECTRUM 77215703 3713732 Live/Registered |
Novartis AG 2007-06-26 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.